Key result
Structural analysis using 13 bovine-derived broadly neutralizing antibodies revealed two cross-protective antigen sites on FMDV serotype O, with antibody C4 potently promoting viral RNA release.
Why the study?
The antigenic structure of FMDV serotype O is complicated, especially regarding sites capable of eliciting a cross-protective neutralizing antibody response.
The study reveals new structural information about cross-protective antigen sites of FMDV serotype O, providing support for future research on broad-spectrum vaccines against FMD.
Identifies cross-protective FMDV O sites for vaccine design; leaves open in vivo efficacy and clinical translation.
FMDV is the causative agent of foot-and-mouth disease (FMD), which is one of the most contagious and economically devastating diseases of domestic animals. The antigenic structure of FMDV serotype O is rather complicated, especially for those sites that can elicit a cross-protective neutralizing antibody response. Monoclonal neutralization antibodies provide both crucial defense components against FMDV infection and valuable tools for fine analysis of the antigenic structure. In this study, we found a cluster of novel VP3-focused epitopes using 13 bnAbs against FMDV serotype O from natural host cattle, which revealed two cross-protective antigen sites on VP2 and VP3. Antibody C4 targeting this novel epitope potently promoted viral particle disassembly and RNA release before infection, which may indicate a vulnerable region of FMDV. This study reveals new structural information about cross-protective antigen sites of FMDV serotype O, providing valuable and strong support for future research on broad-spectrum vaccines against FMD.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) studied Foot-and-mouth disease virus (FMDV) serotype O. Bovine-derived broadly neutralizing monoclonal antibodies (bnAbs) was evaluated on Identification of cross-protective antigen sites and neutralization mechanism. Structural analysis using 13 bovine-derived broadly neutralizing antibodies revealed two cross-protective antigen sites on FMDV serotype O, with antibody C4 potently promoting viral RNA release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: